CXCL13 and neoplasm: Remarkably, these two chemokines were also highlighted by a recent meta-analysis that evaluated existing biomarkers of ICB response (16), suggesting that CXCL9 and CXCL13 are indeed the strongest individual transcriptomic predictors of ICB response independent of tumor type.